Collaborative ventures in the realm of psychedelic drugs embark on a journey, witnessing an impressive 500% surge in 2023.

The realm of psychedelic drugs, encompassing compounds like psilocybin, lysergic acid diethylamide (LSD), and midomafetamine (MDMA), has exhibited substantial potential in addressing conditions such as depression, anxiety disorders, and substance abuse. Notably, partnership deals associated with psychedelic drugs have witnessed an extraordinary 500% surge in total deal volume from 2019 to the current year, with over 40 partnerships forged since 2019, as reported by GlobalData’s Pharma Intelligence Center Deals Database. Despite the classification of psychedelic drugs as Schedule I-controlled substances by the US Drug Enforcement Administration, signifying limited medical value and a high potential for abuse, regulatory agencies like the FDA and EMA have taken strides in recognizing their clinical applicability. This year, both entities issued guideline documentation to support clinical trials and the development of psychedelic drugs. The surge in partnership deals between biopharmaceutical companies and research institutions holds the potential to expedite innovative developments in psychedelic drug therapy. The US leads in the number of private biotech companies engaged in psychedelic drug development, with 63 entities, followed by Canada and the UK with 29 and 15 private biotechs, respectively. Canada, having approved a clinical trial for psilocybin-assisted therapy in August 2020, amended its Special Access Program in January 2022 to enable healthcare practitioners to request access to psychedelic drugs for patients. In September 2023, Canada-based Clearmind Medicine entered a co-development partnership with Johns Hopkins University School of Medicine for a Phase I/II trial of its serotonin receptor 1A agonist, CMND-100, targeting alcohol use disorder. Additionally, Clearmind Medicine collaborated with Hebrew University of Jerusalem and SciSparc in June 2023 to evaluate CMND-100 in combination with SciSparc’s dual cannabinoid receptor agonist palmidrol for obesity and metabolic syndrome treatment. In the same vein, Australia-based Psylo inked a co-development partnership with Daiichi Sankyo to advance its pipeline of non-hallucinogenic psychedelic drugs addressing chronic mental illnesses. Notable candidates include serotonin receptor 2A agonists PSYLO-3001, PSYLO-3002, PSYLO-5001, and PSYLO-1001.